PL3727402T3 - Nanocząstki do zastosowania w zwiększaniu wydajności mózgu lub w leczeniu stresu - Google Patents
Nanocząstki do zastosowania w zwiększaniu wydajności mózgu lub w leczeniu stresuInfo
- Publication number
- PL3727402T3 PL3727402T3 PL18822059.4T PL18822059T PL3727402T3 PL 3727402 T3 PL3727402 T3 PL 3727402T3 PL 18822059 T PL18822059 T PL 18822059T PL 3727402 T3 PL3727402 T3 PL 3727402T3
- Authority
- PL
- Poland
- Prior art keywords
- nanoparticles
- treating stress
- enhancing brain
- brain performances
- performances
- Prior art date
Links
- 210000004556 brain Anatomy 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nanotechnology (AREA)
- Psychology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Medicinal Preparation (AREA)
- Silicon Compounds (AREA)
- Powder Metallurgy (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17306831 | 2017-12-19 | ||
| PCT/EP2018/085689 WO2019121813A1 (en) | 2017-12-19 | 2018-12-18 | Nanoparticles for use in enhancing brain performances or in treating stress |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3727402T3 true PL3727402T3 (pl) | 2025-02-03 |
Family
ID=60957088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18822059.4T PL3727402T3 (pl) | 2017-12-19 | 2018-12-18 | Nanocząstki do zastosowania w zwiększaniu wydajności mózgu lub w leczeniu stresu |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11471482B2 (pl) |
| EP (2) | EP4461363A3 (pl) |
| JP (2) | JP7511900B2 (pl) |
| KR (1) | KR102729932B1 (pl) |
| CN (1) | CN111886014A (pl) |
| AU (1) | AU2018390163B2 (pl) |
| BR (1) | BR112020012215A2 (pl) |
| CA (1) | CA3085534A1 (pl) |
| ES (1) | ES2998117T3 (pl) |
| HU (1) | HUE069335T2 (pl) |
| IL (1) | IL275409B2 (pl) |
| MX (1) | MX2020006361A (pl) |
| NZ (1) | NZ766052A (pl) |
| PL (1) | PL3727402T3 (pl) |
| PT (1) | PT3727402T (pl) |
| UA (1) | UA128391C2 (pl) |
| WO (1) | WO2019121813A1 (pl) |
| ZA (1) | ZA202004343B (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2991899T3 (es) | 2017-12-19 | 2024-12-05 | Nanobiotix | Nanopartículas para su uso para el tratamiento de un trastorno neuronal |
| CA3084780A1 (en) * | 2020-06-24 | 2021-12-24 | Rodney HERRING | Use of low iron oxide iron-doped titanium dioxide nanoparticles in the treatment of tumors and other diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8716220B2 (en) | 2005-09-07 | 2014-05-06 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta |
| AU2007286203B2 (en) | 2006-08-08 | 2013-05-02 | Board Of Regents, The University Of Texas System | Multistage delivery of active agents |
| SG10201908339RA (en) | 2009-07-08 | 2019-10-30 | Clene Nanomedicine Inc | Novel gold-based nanocrystals for medical treatments and electrochemical manufacturing processes therefor |
| RU2552957C2 (ru) | 2010-02-26 | 2015-06-10 | Универсидад Де Наварра | Наночастица (варианты), ее содержащая композиция, включающий названную композицию продукт питания и способ получения наночастиц (варианты) |
| EP2670394B1 (en) | 2011-01-31 | 2018-11-21 | Nanobiotix | Nanoparticles delivery systems, preparation and uses thereof |
| CA2875206C (en) | 2012-06-13 | 2020-07-14 | Cerion Enterprises Llc | Nanoceria for the treatment of oxidative stress |
| EP2974717A3 (en) * | 2014-07-16 | 2016-04-13 | GNT Biotech & Medicals Corporation | Use of nano metal in promoting neurite outgrowth and treatment and/or prevention of neurological disorders |
| JP6778371B2 (ja) * | 2015-01-23 | 2020-11-04 | ミヨシ油脂株式会社 | 金微粒子マトリックスメタロプロテアーゼ阻害剤 |
| US20170290916A1 (en) | 2016-04-07 | 2017-10-12 | The Florida International University Board Of Trustees | Materials and Methods for the Delivery of a Nanocarrier to the Brain |
| WO2018115023A1 (en) | 2016-12-21 | 2018-06-28 | Nanobiotix | Coated nanoparticles for use for modulating electrical polarization of neurons |
| CN110382004A (zh) | 2016-12-21 | 2019-10-25 | 纳米生物技术公司 | 用于治疗神经元障碍的纳米粒子 |
| EA201991521A1 (ru) | 2016-12-21 | 2019-12-30 | Нанобиотикс | Наночастицы для применения для улучшения деятельности мозга или для лечения стресса |
| ES2991899T3 (es) | 2017-12-19 | 2024-12-05 | Nanobiotix | Nanopartículas para su uso para el tratamiento de un trastorno neuronal |
-
2018
- 2018-12-18 PL PL18822059.4T patent/PL3727402T3/pl unknown
- 2018-12-18 IL IL275409A patent/IL275409B2/en unknown
- 2018-12-18 MX MX2020006361A patent/MX2020006361A/es unknown
- 2018-12-18 JP JP2020533828A patent/JP7511900B2/ja active Active
- 2018-12-18 EP EP24202914.8A patent/EP4461363A3/en active Pending
- 2018-12-18 HU HUE18822059A patent/HUE069335T2/hu unknown
- 2018-12-18 CN CN201880086942.2A patent/CN111886014A/zh active Pending
- 2018-12-18 ES ES18822059T patent/ES2998117T3/es active Active
- 2018-12-18 NZ NZ766052A patent/NZ766052A/en unknown
- 2018-12-18 CA CA3085534A patent/CA3085534A1/en active Pending
- 2018-12-18 PT PT188220594T patent/PT3727402T/pt unknown
- 2018-12-18 BR BR112020012215-7A patent/BR112020012215A2/pt unknown
- 2018-12-18 WO PCT/EP2018/085689 patent/WO2019121813A1/en not_active Ceased
- 2018-12-18 AU AU2018390163A patent/AU2018390163B2/en active Active
- 2018-12-18 EP EP18822059.4A patent/EP3727402B1/en active Active
- 2018-12-18 KR KR1020207019896A patent/KR102729932B1/ko active Active
- 2018-12-18 US US16/955,096 patent/US11471482B2/en active Active
- 2018-12-18 UA UAA202004469A patent/UA128391C2/uk unknown
-
2020
- 2020-07-15 ZA ZA2020/04343A patent/ZA202004343B/en unknown
-
2024
- 2024-03-06 JP JP2024033926A patent/JP7758381B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT3727402T (pt) | 2024-11-07 |
| MX2020006361A (es) | 2020-08-17 |
| RU2020123779A (ru) | 2022-01-21 |
| RU2020123779A3 (pl) | 2022-01-21 |
| ES2998117T3 (en) | 2025-02-19 |
| ZA202004343B (en) | 2024-03-27 |
| KR102729932B1 (ko) | 2024-11-13 |
| KR20200111170A (ko) | 2020-09-28 |
| CN111886014A (zh) | 2020-11-03 |
| JP2024069320A (ja) | 2024-05-21 |
| IL275409B1 (en) | 2023-10-01 |
| JP7758381B2 (ja) | 2025-10-22 |
| EP3727402A1 (en) | 2020-10-28 |
| WO2019121813A1 (en) | 2019-06-27 |
| EP4461363A3 (en) | 2025-01-08 |
| UA128391C2 (uk) | 2024-07-03 |
| JP2021507903A (ja) | 2021-02-25 |
| JP7511900B2 (ja) | 2024-07-08 |
| EP4461363A2 (en) | 2024-11-13 |
| AU2018390163B2 (en) | 2024-05-02 |
| US20200405750A1 (en) | 2020-12-31 |
| IL275409B2 (en) | 2024-02-01 |
| BR112020012215A2 (pt) | 2020-11-24 |
| IL275409A (en) | 2020-07-30 |
| HUE069335T2 (hu) | 2025-02-28 |
| EP3727402B1 (en) | 2024-10-09 |
| CA3085534A1 (en) | 2019-06-27 |
| US11471482B2 (en) | 2022-10-18 |
| NZ766052A (en) | 2025-09-26 |
| AU2018390163A1 (en) | 2020-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274769A (en) | Use of cannabinoids in the treatment of epilepsy | |
| GB2568809B (en) | Use of cannabinoids in the treatment of epilepsy | |
| IL269371A (en) | Treatment methods | |
| GB2568471B (en) | Use of cannabinoids in the treatment of epilepsy | |
| IL279308A (en) | Methods for the treatment of heptidine-mediated disorders | |
| IL267407A (en) | Nanoparticles for use to improve brain performance or treat stress | |
| PT3334422T (pt) | Utilização de ácido canabidiólico no tratamento de epilepsia | |
| IL259570A (en) | Combined therapy and their uses and methods | |
| ZA201705673B (en) | Methods for treating skin | |
| GB201510664D0 (en) | Use of cannabinoids in the treatment of epilepsy | |
| IL255780A (en) | Therapeutic combinations and methods for treating neoplasia | |
| GB201411496D0 (en) | Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy | |
| GB201418171D0 (en) | Use of cannabidiol in the treatment of intractable epilepsy | |
| GB201418170D0 (en) | Use of cannabidiol in the treatment of intractable epilepsy | |
| GB201418166D0 (en) | Use of cannabidiol in the treatment of intractable epilepsy | |
| IL251215A0 (en) | Cannabinoid preparation and method for treating pain | |
| GB201418169D0 (en) | Use of cannabidiol in the treatment of intractable epilepsy | |
| GB201418172D0 (en) | Use of cannabidiol in the treatment of intractable epilepsy | |
| GB201608885D0 (en) | Treatment | |
| SMT202400023T1 (it) | Alprazolam per l’uso nel trattamento dell’epilessia | |
| SG11201704829QA (en) | Methods and compositions for treating brain diseases | |
| IL252904A0 (en) | Methods and factors for treating diseases | |
| IL276431A (en) | Treatment of the brain disorders and related symptoms | |
| IL275409A (en) | Nanoparticles for use to improve brain performance or treat stress | |
| IL255012A0 (en) | Preparations and methods for treating skin conditions |